New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
10:05 EDTWYNN, TBPH, MSG, ITMN, FN, VSAT, SEAS, LVMUY, INFY, ADDYY, URS, QLYS, JONE, FCXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adidas (ADDYY) downgraded to Neutral from Buy at Goldman... Fabrinet (FN) downgraded at B. Riley... Freeport McMoRan (FCX) downgraded at Stifel... Infosys (INFY) downgraded to Hold from Buy at Jefferies... InterMune (ITMN) downgraded to Neutral from Buy at Goldman... Jones Energy (JONE) downgraded to Neutral from Overweight at JPMorgan... LVMH Moet Hennessy (LVMUY) downgraded to Neutral from Buy at Goldman... Madison Square Garden (MSG) downgraded to Hold from Buy at Topeka... Qualys (QLYS) downgraded to Sector Perform from Outperform at RBC Capital... SeaWorld (SEAS) downgraded to Market Perform from Outperform at Wells Fargo... Theravance Biopharma (TBPH) downgraded to Underperform from Neutral at RW Baird... URS Corporation (URS) downgraded to Neutral from Buy at Sterne Agee... ViaSat (VSAT) downgraded to Perform from Outperform at Oppenheimer... Wynn Resorts (WYNN) downgraded to Hold from Buy at Gabelli.
News For ADDYY;FN;FCX;INFY;ITMN;JONE;LVMUY;MSG;QLYS;SEAS;TBPH;URS;VSAT;WYNN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
10:27 EDTFCXFreeport McMoRan sees FY16 sales of copper 5.4B pounds, sales of gold 1.9M oz
Subscribe for More Information
10:12 EDTFCXFreeport McMoRan says improving operating trends at Grasberg
Subscribe for More Information
10:10 EDTFCXFreeport McMoRan says company highly leveraged to copper prices
Slowdown of economy in China has had an impact. Doesn't see a hard landing for China economy. Comments made on Q2 earnings call.
08:13 EDTTBPHTheravance Biopharma announces approval of Vibativ in Canada
Theravance Biopharma announced that Health Canada has approved Vibativ for the treatment of adult patients with hospital-acquired bacterial pneumonia, or HAP, and ventilator-associated bacterial pneumonia, or VAP, known or suspected to be caused by susceptible isolates of Staphylococcus aureus including methicillin-susceptible and methicillin-resistant S. aureus, or MSSA and MRSA. Vibativ is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat pathogens such as MRSA. The antibiotic is also currently approved in Canada for the treatment of patients with complicated skin and skin structure infections, or cSSSI, caused by susceptible strains of Gram-positive microorganisms. Vibativ will be marketed and sold in Canada by PENDOPHARM, a division of Pharmascience Inc., and is expected to become commercially available in 2016. This marketing clearance triggers a milestone payment to Theravance Biopharma under terms of its development and commercialization agreement with PENDOPHARM. Additional terms of this agreement call for Theravance Biopharma to receive potential future contingent payments and a royalty on net sales of Vibativ from PENDOPHARM.
08:07 EDTFCXFreeport McMoRan files registration statement for possible IPO of O&G stake
Subscribe for More Information
08:05 EDTFCXFreeport McMoRan sees consolidated sales of 1B pounds of copper in Q3
Subscribe for More Information
08:04 EDTFCXFreeport McMoRan sees consolidated sales of 4.2B pounds of copper in FY15
Subscribe for More Information
08:02 EDTFCXFreeport McMoRan reports Q2 adjusted EPS 14c, consensus 7c
Subscribe for More Information
07:32 EDTWYNNLas Vegas Sands results encouraging, says Stifel
After Las Vegas Sands (LVS) reported higher than expected Macau property-level EBITDA, Stifel says that the beat should cause analysts to raise their estimates for the company. The firm adds that the results are encouraging for all "Macau-centric operators." It raised its price target on Las Vegas Sands to $65 from $60 and keeps a Buy rating on the shares. Other companies with a major presence in Macau include Melco Crown (MPEL), Wynn Resorts (WYNN), and MGM (MGM).
July 22, 2015
19:02 EDTWYNNOn The Fly: After Hours Movers
Subscribe for More Information
13:47 EDTFCXEarnings Watch: Morgan Stanley positive on Freeport-McMoRan ahead of Q2 results
Freeport-McMoRan (FCX) is expected to report second quarter earnings on Thursday, July 23, before the market open with a conference call scheduled for 10:00 am ET. Freeport-McMoRan is a natural resource company with an industry portfolio of mineral assets, oil and natural gas resources, and a production profile. EXPECTATIONS: Analysts are looking for earnings per share of 7c on revenue of $4.28B, according to First Call. The consensus range for EPS is (15c)-17c on revenue of $3.68B-$5.11B. LAST QUARTER: Freeport-McMoRan reported first quarter adjusted EPS of (6c) against estimates for (7c), on revenue of $4.15B against estimates for $4.06B. Consolidated sales for Q1 totaled 960M pounds of copper, 263K ounces of gold, 23M pounds of molybdenum and 12.5M barrels of oil equivalents, compared with 871M pounds of copper, 187K ounces of gold, 27M pounds of molybdenum and 16.1 MMBOE in Q1 of last year. Consolidated sales for 2015 are expected to approximate 4.2B pounds of copper, 1.3M ounces of gold, 95M pounds of molybdenum and 52.3 MMBOE. The company forecast FY16 sales of copper at 5.4B pounds and sales of gold at 1.9M oz. It sees FY17 sales of copper at 5B pounds and sales of gold at 2.4M oz. Capital expenditures are expected to approximate $6.5B for 2015, including $2.5B for major projects at mining operations and $2.8B for oil and gas operations. Freeport-McMoRan said it has taken actions to reduce or defer capital expenditures and other costs and is evaluating funding alternatives to advance growth projects in its oil and gas business, including consideration of a sale of public equity for a minority interest in its oil and gas subsidiary. On its Q1 conference call, management said they were optimistic for mid-term and long-term prospects for business. STREET RESEARCH: Sentiment on the Street leading up to Freeportís Q2 report has been positive. On April 28, Morgan Stanley upgraded Freeport-McMoRan to Overweight from Equal Weight with a $29 price target. The firm had reduced concerns about financing due to ramping volumes and cost declines. Morgan Stanley believed Freeport-McMoRan's copper growth projects were near an inflection point and production increases would drive a 28% volume increase at a lower cost and reduced capex. On June 9, Morgan Stanley said Freeport-McMoRanís valuation was attractive. The firm believed Freeport's Q1 was a multi-year trough for earnings and free cash flow. Morgan Stanley saw minimal execution risk at three key projects and expected costs to decline 22% in 2016. Morgan Stanley viewed Freeport's valuation as attractive and reiterated its Overweight rating and $29 price target. PRICE ACTION: Freeportís shares are down about 25% since the company's Q1 report and have plummeted more than 60% over the past twelve months. In afternoon trading ahead of Thursday's Q2 report, Freeportís shares are down about 4.7%.
10:15 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
08:01 EDTADDYYSL Green signs Adidas to retail lease at 115 Spring Street
Subscribe for More Information
July 21, 2015
10:24 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
05:29 EDTINFYInfosys sees FY15 IFRS revenue up 7.2%-9.2% in USD terms
Subscribe for More Information
05:28 EDTINFYInfosys reports Q1 EPS 21c, consensus 21c
Subscribe for More Information
July 20, 2015
14:44 EDTINFYInfosys volatility increases into Q1 and outlook
Infosys August call option implied volatility is at 34, September is at 29; compared to its 52-week range of 21 to 41, suggesting large near term price movement into the expected release of Q1 results on July 21.
13:16 EDTINFYInfosys technical comments ahead of results
The stock has been trading in a sideways range for the last several weeks bound by $15.25 at the low and $16.35 at the high. If the news is bullish, a breakout above the range at $16.35 would see next resistance at $17.05. Thereafter resistance would be at $17.70 and $18.18. If the news is bearish, a breakdown below $15 would see next support at $14.61. The irregularly-shaped potential head and shoulders pattern would also become active. That pattern could reach the $12 to $11.50 area over time if nothing interrupts its progress.
13:10 EDTFCXFreeport McMoRan 30-day call volatility increases as gold pulls back
Subscribe for More Information
10:00 EDTFCXFreeport McMoRan hits new 52-week low, levels to watch
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use